Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 255

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 255
---
 |   |     |     | December 31, 
         2023 |   |
|:-------------------|:----|:----|----------:|:--|:----|:----|-------------:|:--|
| Number of warrants |     |     |    66,946 |   |     |     |       66,946 |   |
| Discount rate      |     |     |        30 | % |     |     |           30 | % |
| Term (years)       |     |     | 0.75-0.92 |   |     |     |         0.25 |   |
| Fair value         |     |     |       148 |   |     |     |          221 |   |

The following table presents changes
in the fair value of the warrant liability:

| Balance as of January 1, 2024 |     | $ | 221 |   |
| Changes in fair value         |     |   | (73 | ) |
| Balance as of June 30, 2024   |     | $ | 148 |   |
| Balance as of January 1, 2023 |     | $ | 278 |   |
| Changes in fair value         |     |   | (56 | ) |
| Balance as of June 30, 2023   |     | $ | 222 |   |

The Company has performed a sensitivity
analysis of the warrant liability which is classified as level 3 financial instruments. The Company recalculated the value of the warrants
by applying a +/- 5.0% changes to the input variables in PWERM. As of June 30, 2024, a 5.0% decrease in discount rate would increase
the fair value of the warrants to $154; a 5.0% increase in discount rate would decrease the fair value of the warrants to $143.

| b. | On March 11, 2023, the Company issued                                                           
 53,031 warrants in connection with the issuance of its convertible notes. which are exercisable 
 into convertible preferred D-2 shares. The warrants were exercisable until December 31, 2023    
 and have expired on December 31, 2023, as they were not exercised.                              |

<div align='center'>F-11</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED